ExpreS2ion announces the initiation of a Phase I/IIa clinical trial for a new blood-stage malaria vaccine
October 18, 2016 04:00 ET
|
ExpreS2ion Biotech Holding AB
Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB
(“ExpreS2ion”) announces that its collaboration partner, the Jenner Institute of
the University of Oxford, initiates a Phase...
ExpreS2ion meddelar inledande av klinisk fas I/IIa-studie avseende nytt vaccin mot malaria i blodfas
October 18, 2016 04:00 ET
|
ExpreS2ion Biotech Holding AB
Hørsholm, Danmark – ExpreS2ion Biotech Holding AB (”ExpreS2ion”) meddelar idag,
den 18. Oktober, att bolagets samarbetspartner, the Jenner Institute vid
universitetet i Oxford, inleder en klinisk fas...
ExpreS2ion och VaxInnate tecknar avtal om forskningslicens
September 20, 2016 06:00 ET
|
ExpreS2ion Biotech Holding AB
Hørsholm, Danmark, 20 september 2016 – ExpreS2ion Biotech Holding AB
(“ExpreS2ion”) och VaxInnate Corporation (”VaxInnate”) meddelar idag att de har
tecknat ett avtal gällande en forskningslicens...
ExpreS2ion and VaxInnate Sign Research License Agreement
September 20, 2016 06:00 ET
|
ExpreS2ion Biotech Holding AB
Horsholm, Denmark, September 20, 2016 – Today, ExpreS2ion Biotech Holding AB
(“ExpreS2ion”), and VaxInnate Corporation (“VaxInnate”) announce that they have
signed a Research License Agreement under...
ExpreS2ion Biotech Holding AB publicerar delårsrapport för januari – juni 2016
August 31, 2016 03:00 ET
|
ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (”ExpreS2ion”) publicerar härmed delårsrapport
avseende perioden januari till juni 2016. Rapporten finns tillgänglig på
bolagets hemsida www.expres2ionbio.com. Nedan...
ExpreS2ion Biotech Holding AB: Första dag för handel på Nasdaq Stockholm First North
July 29, 2016 02:00 ET
|
ExpreS2ion Biotech Holding AB
Idag, den 29 juli 2016, inleds handeln i ExpreS2ion Biotech Holding AB's
(”ExpreS2ion”) aktier på Nasdaq Stockholm First North.
Handel med ExpreS2ions aktier på Nasdaq Stockholm First North inleds...
ExpreS2ion Biotech announces clinical trial update for the PamVac (Placental Malaria Vaccine) phase I study
July 28, 2016 06:00 ET
|
ExpreS2ion Biotech Holding AB
PamVac (Placental Malaria Vaccine) phase I study
ExpreS2ion Biotech announces the second successful evaluation of safety by the
independent safety monitoring board for the phase Ia clinical trial of...